A hope for Alzheimer’s: Lecanemab breakthrough from the research community
22 December 2022
The companies Eisai (JP) and Biogen (USA) recently announced promising results from their Phase 3 clinical study of lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD. [...] Read More